By Julia Karow

GnuBio plans to release a beta version of its desktop microfluidic sequencer in the second quarter and to launch the system commercially by the end of the year, the company said earlier this month.

The firm plans to focus on gene panel resequencing and replacing Sanger-based single-gene assays with its instrument, which integrates target amplification, sequencing, and data analysis. GnuBio promises its customers low cost, high accuracy, and fast turnaround times.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.